If you’re a federal employee and have questions about continuing coverage, please speak to your Patient Benefits Specialist and visit our insurance page here: virginiacancerspecialists.com/insurance/.
A radioconjugate composed of gilteritinib, an inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246), labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of gilteritinib. Gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL and ALK. This may result in an inhibition of FLT3, AXL, and ALK-mediated signal transduction pathways and the reduction of tumor cell proliferation in cancers that overexpress these RTKs. Labeling of gilteritinib with the radioactive tracer carbon C 14 allows for the evaluation of gilteritinib’s pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME). Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
